iPSC-derived RPE cells
Age-Related Macular Degeneration
Preclinical/ResearchActive
Key Facts
About Healios
Healios develops iPSC-based regenerative therapies for ophthalmology, ARDS, and oncology, aiming to deliver cures for intractable diseases.
View full company profileTherapeutic Areas
Other Age-Related Macular Degeneration Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (AMD) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| hOTX2 | BrainEver | Discovery |
| DARC for AMD | Novai | Exploratory Biomarker in Clinical Studies |
| Undisclosed AMD Program | Mobius Scientific | Preclinical |